Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next
Bharat Biotech is “back in action” after a two-year post-Covid reset, founder Krishna Ella says, with the company expanding beyond vaccines into cell and gene therapy and monoclonal antibodies. The vaccine maker is advancing programmes for TB, Nipah, Ebola, chikungunya, malaria, Zika and antimicrobial resistance, while exploring an IPO to fund new therapies and potential acquisitions. Ella says the company, which currently has around Rs 2,000 crore in revenue and is debt-free, is focused on accelerating innovation and preparing the next generation to lead its human and veterinary businesses.
RSS News
Economic times
0 thoughts on “Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- IND vs WI: Captain Shubman Gill did not even defend 351 runs
- Kerala govt orders probe against Gyanesh Kumar: 2006 PWD engineer's suicide case; Chief Election Commissioner was the secretary in the state at that time
- From 'Neerja' to 'Bell Bottom', 10 films made on plane hijack and crisis
- Floods in UP's Lucknow, 10,000 evacuated: 27 dead, 20 missing in Bihar; Monsoon leaves 4 states, including Rajasthan, Madhya Pradesh
- Asian Games 2026: India finishes on a grand note, wins a total of 85 medals, including 21 golds
